News

November 13, 2019November 13, 2019

Anifrolumab Reduces Disease Activity, Skin Lesion Severity, and Corticosteroid Use in SLE Patients, Phase 3 Trial Shows

News

Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a ... Read more

November 11, 2019November 11, 2019

Blood Protein Levels Linked to Disease Activity in Children with SLE and May Be Biomarkers, Study Reports

News

Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium — are higher in children and adolescents with systemic lupus erythematosus (SLE) and ... Read more

November 8, 2019

Predictors of Treatment Response, Evidence of Reduced Disease Activity Among New Data on Stelara

News

Higher expression of nine genes may help identify people with systemic lupus erythematosus (SLE) who will respond to treatment with Stelara (ustekinumab) — an approved therapy in inflammatory disorders but not ... Read more

November 6, 2019November 6, 2019

European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

News

A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including systemic ... Read more

November 4, 2019November 4, 2019

Using Hydroxychloroquine for Less Than 1 Year Raises Patients’ Likelihood of Flares, Study Suggests

News

People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start are at a higher risk of flares than those who continue ... Read more

November 1, 2019November 1, 2019

Benlysta Approved in Europe for Children with SLE Starting at Age 5

News

The European Commission has approved the use of intravenous Benlysta (belimumab) as an add-on to standard therapy for children ages 5 and older with systemic lupus erythematosus (SLE) and high disease activity. “This ... Read more

October 30, 2019

More Than 40% of SLE Patients Do Not Adhere to Hydroxychloroquine Therapy, Study Reports

News

More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among people who have insurance coverage, low copayments, and availability of high ... Read more

October 28, 2019October 28, 2019

Phase 3 Trial of Voclosporin for Lupus Nephritis Completes Study Visits, Results Expected Soon

News

A Phase 3 trial assessing the potential of voclosporin as an add-on to standard treatment for people with lupus nephritis has completed patient visits. “With the completion of patient ... Read more

October 25, 2019October 25, 2019

Expanding ‘Us in Lupus’ Effort, GSK Focuses on Women of Color

News

Expanding its Us in Lupus effort, GlaxoSmithKline (GSK) has planned “Night of Beauty” events to reach women of color, a group disproportionately affected by this disease. Us in Lupus is ... Read more

October 23, 2019October 25, 2019

Low-dose IL-2 Reduces Disease Activity in SLE, Trial Results Suggest

News

Adding low-dose interleukin-2 (IL-2) to standard therapy increases responses and complete remission of lupus nephritis in patients with systemic lupus erythematosus (SLE), results of a randomized clinical trial suggest. ... Read more

This is a short description about myself and what this site is about. I hope you enjoy being here!

News

Anifrolumab Reduces Disease Activity, Skin Lesion Severity, and Corticosteroid Use in SLE Patients, Phase 3 Trial Shows

Blood Protein Levels Linked to Disease Activity in Children with SLE and May Be Biomarkers, Study Reports

Predictors of Treatment Response, Evidence of Reduced Disease Activity Among New Data on Stelara

European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

Using Hydroxychloroquine for Less Than 1 Year Raises Patients’ Likelihood of Flares, Study Suggests

Benlysta Approved in Europe for Children with SLE Starting at Age 5

More Than 40% of SLE Patients Do Not Adhere to Hydroxychloroquine Therapy, Study Reports

Phase 3 Trial of Voclosporin for Lupus Nephritis Completes Study Visits, Results Expected Soon

Expanding ‘Us in Lupus’ Effort, GSK Focuses on Women of Color

Low-dose IL-2 Reduces Disease Activity in SLE, Trial Results Suggest

Pin It on Pinterest